Clinical trials: glp1 Agonist
Diabetic Kidney Disease, Type 1 Diabetes
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes.
- Trial name
- RT1D (NCT05822609)
- Testing
- Semaglutide
- Where
- 4 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- University of Washington
Overweight and Obesity, Healthy
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg twice daily [BID]) or placebo for 5 days beginning on Day 1.
- Trial name
- NCT06500429
- Testing
- NG101, Semaglutide Injectable Product
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Neurogastrx, Inc.
Crohn Disease
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
The purpose of this study is to use diet and an injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication as adjunctive…
- Trial name
- NCT06774079
- Testing
- Tirzepatide, Mediterranean diet
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Miami
Type 2 Diabetes Mellitus, Mild Cognitive Impairment
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
This is an investigator-led prospective, randomized, open label, parallel study to explore and evaluate the therapeutic effects of Liraglutide, Empagliflozin and Linagliptin on the cognitive function in T2DM patients with mild…
- Trial name
- LIGHT-MCI (NCT05313529)
- Testing
- Liraglutide, Empagliflozin, Linagliptin
- Where
- 5 sites in China
- Volunteers
- 396 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Type 2 Diabetes (T2DM)
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Minorities have higher rates of diabetes, poorer glucose control, and higher complications and mortality rates than white people.
- Trial name
- Beta (NCT07325435)
- Testing
- SGLT-2 inhibitor, GLP1-RA
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- MaryAnn Banerji
Non-diabetec Obesity, Obesity (Disorder)
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults.
- Trial name
- NCT07834398
- Testing
- Dulaglutide, Semagludtide, Tirzepatide
- Where
- Saudi Arabia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Weight Loss, NASH
Phase 1 Study to Evaluate the Safety and Tolerability of VK2735
This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VK2735 in healthy adults and…
- Trial name
- NCT05203237
- Testing
- VK2735, VK2735 Drug
- Where
- Australia
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Viking Therapeutics, Inc.
Type 2 Diabetes
Effect of GLP-1 on Angiogenesis
GLP-1 receptor agonists are introduced in the treatment of type 2 Diabetes (T2D) and their efficacy is documented. However, safety aspects are also important to evaluate with respect to micro and macrovascular complications…
- Trial name
- ANGIOSAFE 1 (NCT02686177)
- Testing
- Liraglutide, Metformin or sulfonylurea
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Embolism
Semaglutide Use in Acute Pulmonary Embolism
Evaluation of circulating endothelial inflammatory biomarkers in response to GLP-1 agonist Semaglutide in acute pulmonary embolism
- Trial name
- NCT06118203
- Testing
- Semaglutide
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Imperial College London
Obesity-related Male Infertility
Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health
Why is this study being done? Obesity can harm men's fertility by lowering sperm quality and hormone levels, making it harder to have children. Weight loss through diet and exercise helps, but it's often hard to stick with.
- Trial name
- NCT07179120
- Testing
- Semaglutide (Rybelsus®), Tirzepatide, Standardized Lifestyle Intervention
- Volunteers
- 180 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Metabolic Syndrome
Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)
This study is a randomized, parallel-group, observer-masked clinical trial. A total of 200 obese participants with MetS will be enrolled.
- Trial name
- NCT06271200
- Testing
- Strategic lifestyle and drug interventions, Control
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Health Research Institutes, Taiwan
Gestational Diabetes Mellitus (GDM), Metabolic Syndrome
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
This is an effectiveness-implementation Hybrid Type 1 study using a randomized clinical trial design to evaluate the effectiveness and potential real-world integration of immediate postpartum semaglutide following a pregnancy…
- Trial name
- NCT07797036
- Testing
- Semaglutide (Wegovy) weekly injection
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- University of Massachusetts, Worcester
Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B), Hepatic Insufficiency (MeSH ID: D048550)
Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment
This is a Phase I, single-center, open-label, parallel-group study. A single oral dose of MDR-001, a GLP-1 receptor agonist, will be administered to participants with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic…
- Trial name
- NCT07550634
- Testing
- MDR-001
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- MindRank AI Ltd
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 2 (NCT05259033)
- Testing
- IcoSema, Semaglutide 1 mg
- Where
- 193 sites in United States, Brazil and 13 more
- Volunteers
- 683 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GETGOAL-L-ASIA (NCT00866658)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 4 sites in Japan, Philippines and 2 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Obesity, Type 2 Diabetes Mellitus (T2DM)
Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study
An observational study of those who have been prescribed a GLP-1 agonist therapy (yet to commence), for either weight or diabetes management, and are willing to complete dietary records and questionnaires of behaviour and…
- Trial name
- GLaD (NCT07001553)
- Where
- Australia
- Volunteers
- 37 people
- Sponsor
- Australian Catholic University
Weight Loss
High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)
The primary objective of this study is to examine the effects of a high-protein diet (HP) paired with resistance training (RT) compared with a HP diet alone, on skeletal muscle mass (SMM) volume of the (a) quadriceps and (b)…
- Trial name
- NCT07700030
- Testing
- High protein diet, Resistance Training (RT) Programs
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- NYU Langone Health
Obesity (Disorder), Anti-obesity Agents
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.
Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1…
- Conditions
- Obesity (Disorder), Anti-obesity Agents, Precision Medicine
- Trial name
- Diagenix (NCT07653412)
- Testing
- Semaglutide or Tirzepatide
- Where
- Greece
- Volunteers
- 220 people
- Sponsor
- National and Kapodistrian University of Athens
Obesity, Muscle Loss
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass.
- Trial name
- PROACT (NCT07101939)
- Testing
- (S)-pindolol benzoate, Semaglutide
- Where
- 7 sites in Serbia
- Volunteers
- 120 people
- Sponsor
- Actimed Therapeutics Ltd
Type 2 Diabetes Mellitus, Obesity
The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity
The goal of this study is to learn whether semaglutide (treatment for type 2 diabetes and obesity) can improve signs and symptoms of hypogonadism in men with type 2 diabetes, obesity and hypogonadism (a condition when levels of…
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Functional Hypogonadism
- Trial name
- SEMAT (NCT06489457)
- Testing
- Semaglutide, Testosterone Undecanoate
- Where
- Slovenia
- Volunteers
- 25 people
- Sponsor
- University Medical Centre Ljubljana